[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100479176":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":66,"collaborators":11,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":11,"eligibilityCriteria":73,"healthyVolunteers":70,"sex":74,"minAge":75,"maxAge":11,"enrollmentInfo":76,"targetDuration":11,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":11,"overallStatus":39,"whyStopped":11,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Northside Hospital, Inc.","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intrathecal chemotherapy before blinatumomab","EXPERIMENTAL",null,[13,14],"Drug: Methotrexate","Drug: Blinatumomab",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":11},"DRUG","Methotrexate","Methotrexate 12mg given intrathecally within 24 hours prior to blinatumomab administration",[9],{"type":17,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"Blinatumomab","Blinatumomab 28ug\u002Fday continuous infusion for 4 weeks",[9],[26],{"name":27,"affiliation":28,"role":29},"Melhem Solh, MD","Blood and Marrow Transplant Group of Georgia","PRINCIPAL_INVESTIGATOR",[31],{"name":32,"role":33,"phone":34,"phoneExt":11,"email":35},"Caitlin Guzowski","CONTACT","404-851-8523","caitlin.guzowski@northside.com",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Northside Hospital","RECRUITING","Atlanta","Georgia","30342","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-84.38798,33.749,{"lat":49,"lon":48},[52,54,57,59,61,63,64],{"name":53,"role":33,"phone":34,"phoneExt":11,"email":35},"Caitlin Guzowski, MBA, MHA",{"name":55,"role":56,"phone":11,"phoneExt":11,"email":11},"H. Kent Holland, MD","SUB_INVESTIGATOR",{"name":58,"role":56,"phone":11,"phoneExt":11,"email":11},"Asad Bashey, MD",{"name":60,"role":56,"phone":11,"phoneExt":11,"email":11},"Lawrence E Morris, MD",{"name":62,"role":56,"phone":11,"phoneExt":11,"email":11},"Scott Solomon, MD",{"name":27,"role":29,"phone":11,"phoneExt":11,"email":11},{"name":65,"role":56,"phone":11,"phoneExt":11,"email":11},"Lizamarie Bachier-Rodriguez, MD",{"type":67,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100479176","phase-2-intrathecal-chemoprophylaxis-to-prevent-neurotoxicity-associated-with-blinatumomab-therapy-for-acute-lymphoblastic-leukemia-100479176",false,"NCT05519579","Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\n* Adults receiving first cycle of blinatumomab for relapse\u002Frefractory or MRD-positive B-cell Acute Lymphoblastic Leukemia\n* Adequate renal and hepatic function\n* Negative for HIV\n* Negative serum pregnancy test, if applicable\n* ECOG 0-2\n\nExclusion Criteria:\n\n* Active CNS involvement by ALL\n* Relative CNS disorders (seizure, paresis, aphasia, Cerebrovascular ischemia\u002Fhemorrhage, severe brain injury, dementia, Parkinson's, cerebellar disease, psychosis, coordination or movement disorder)\n* Contraindication to receive intrathecal methotrexate\n* Prior treatment with blinatumomab\n* Active malignancy other than ALL\n* Active infection or any other concurrent disease or medical condition that was deemed to interfere with the conduct of the study as judged by the investigator","ALL","18 Years",{"count":77,"type":78},20,"ESTIMATED","INTERVENTIONAL",[81],"PHASE2","Changing the schedule of intrathecal chemotherapy to be given before and during blinatumomab will maintain the anti-leukemic effects of this drug while at the same time adding the benefit of limiting the neurotoxicity associated with cytokine release.",[84],"Acute Lymphoblastic Leukemia","2026-04-15",{"date":87,"type":88},"2026-04-20","ACTUAL",{"date":90,"type":88},"2023-06-30",{"date":92,"type":78},"2026-12-01",{"name":5,"class":6},1]